Foghorn Therapeutics (FHTX) Total Liabilities (2019 - 2026)

Foghorn Therapeutics' Total Liabilities history runs 8 years deep, the most recent figure standing at $298.6 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 6.8% year-over-year to $298.6 million; the TTM figure through Mar 2026 stood at $298.6 million (down 6.8% YoY), while the FY2025 annual figure was $306.6 million, down 6.95% from the prior year.
• Total Liabilities was $298.6 million for Q1 2026 at Foghorn Therapeutics, down from $306.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $415.9 million in Q1 2022 to a low of $294.6 million in Q3 2025.
• Historically, Total Liabilities has averaged $355.6 million across 5 years, with a median of $352.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 297.15% in 2022, then fell 12.49% in 2025.
• A 5-year view of Total Liabilities shows it stood at $404.8 million in 2022, then fell by 10.29% to $363.1 million in 2023, then decreased by 9.25% to $329.5 million in 2024, then slipped by 6.95% to $306.6 million in 2025, then fell by 2.62% to $298.6 million in 2026.
• The last three Total Liabilities figures came in at $298.6 million (Q1 2026), $306.6 million (Q4 2025), and $294.6 million (Q3 2025), per Business Quant data.